Search Medical Condition
Please enter condition
Please choose location

Buxtehude, Germany Clinical Trials

A listing of Buxtehude, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (31) clinical trials

Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon

Arm A: Interferon-alpha-2b 20 MIU/m2 for 4 weeks. 5 days a week i.v followed by 48 weeks of treatment with 3 x 10 MIU/m2 s.c Arm B: Interferon-alpha-2b 20 MIU/m2 for 4 weeks. 5 days a week i.v repeated 3 times with 12 treatment-free-weeks between the cycles Secondary endpoints: Improved ...

Phase

0.44 miles

Learn More »

Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies Versus Observation

This is a national, open-label, randomized, multicenter phase II study to assess the efficacy of adjuvant therapy with immune checkpoint blocking antibodies in completely resected Merkel cell carcinoma (MCC) patients. MCC is a rare (incidence of 0.44 per 100,000), highly aggressive form of skin cancer. Indeed, MCC has a dramatically ...

Phase

0.44 miles

Learn More »

Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma

Study Phase I: Run-In-Phase Based on acceptable safety data for nintedanib monotherapy, a rapid dose finding will be conducted in a classical 3+3 design. Predefined dose levels are 150 mg (dose level 1) and 200 mg (dose level 2) nintedanib, twice daily, with weekly paclitaxel 90 mg/m2. Study Phase II ...

Phase

0.44 miles

Learn More »

A Study of Otezla in Patients With Plaque Psoriasis Under Routine Conditions

The objective of this NIS (according to section 67(6) of the German Medicinal Products Act) is the documentation of data on the effectiveness and tolerability of an Apremilast treatment under routine clinical conditions in German patients with plaque psoriasis. This NIS is intended to reflect the apremilast treatment of patients ...

Phase N/A

0.44 miles

Learn More »